DUBLIN--(BUSINESS WIRE)--The "Risk-based Monitoring Software Market by End User (Pharma & Biopharmaceutical Co., Medical Device Co., CROs), Delivery Mode (Web Hosted, On-premise, Cloud-based), Type (Enterprise, Site), Component (Software, Services) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
The global RBM software market is projected to reach USD 511.1 million by 2025 from USD 273.7 million in 2020, at a CAGR of 13.3% during the forecast period. Oracle (US), Medidata Solutions (US), and Parexel International Corporation (US) were the leading players in the RBM software market.
The RBM software market has witnessed various advancements in products and their approvals to meet the needs of the pharmaceutical research and development industry worldwide.
Growth in the market can primarily be attributed to factors such as the cost and time efficiency of RBM solutions, rising number of clinical trials, and increasing government funding and grants to support clinical trials
The Enterprise RBM Software segment to hold the largest market share in 2020.
Based on type, the RBM software market is segmented into Enterprise RBM Software and Site RBM Software. In 2020, the Enterprise RBM Software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the widespread adoption of enterprise RBM software by end-users as it allows all authorized professionals to have access to clinical trial data and metrics placed at a centralized location.
The software component segment to hold the largest market share in 2020.
Based on the component, the RBM software market is segmented into Software and Services. In 2020, the software segment is expected to command the largest share of the RBM software market. The large share of this segment can be attributed to the increasing R&D expenditure in the life science and clinical research industries, increasing number of clinical trials, and rising customer base
The pharmaceutical and biopharmaceutical companies segment to hold the largest market share in 2020.
Based on end-user, the RBM software market is segmented into pharmaceutical and biopharmaceutical companies, CROs, medical device companies, and other end users. In 2020, the pharmaceutical and biopharmaceutical companies segment is expected to command the largest share of the RBM software market. The increasing R&D expenditure of pharmaceutical and biopharmaceutical companies is the major factor driving the growth of this end-user segment.
The Asia Pacific region to witness the highest growth during the forecast period.
Geographically, North America dominated the global RBM software market in 2020. However, the Asia Pacific market is expected to register the highest during the forecast period. The major factors driving the growth of the Asia Pacific market include increasing government funding to support clinical trials, the presence of less stringent regulatory guidelines as compared to developed nations, a large patient base, low operating costs for conducting clinical trials, shortage of trial volunteers in Europe and North America, and the growing number of pharmaceutical companies and CROs in the region.
Key Topics Covered
2 Research Methodology
3 Executive Summary
4 Premium Insights
4.1 Risk-Based Monitoring Software: Market Overview
4.2 Risk-Based Monitoring Software Market Share, by Type, 2020 vs. 2025
4.3 Risk-Based Monitoring Software Market Share, by Component, 2020 vs. 2025
4.4 Risk-Based Monitoring Software Market: Geographic Growth Opportunities
5 Market Overview
5.2 Market Dynamics
188.8.131.52 Cost and Time Efficiency of RBM Solutions
184.108.40.206 Rising Number of Clinical Trials
220.127.116.11 Increasing Government Funding and Grants to Support Clinical Trials
18.104.22.168 High Implementation Costs
22.214.171.124 Increased Outsourcing of Clinical Trial Processes to CROs
126.96.36.199 Dearth of Skilled Professionals for Operating RBM Solutions
6 Risk-Based Monitoring Software Market, by Type
6.2 Enterprise RBM Software
6.2.1 Enterprise RBM Software Dominates the RBM Software Market
6.3 Site RBM Software
6.3.1 Site RBM Software Offers Improved Trial Management
7 Risk-Based Monitoring Software Market, by Component
7.2.1 Growing Adoption of Clinical Trial Management Solutions to Support Market Growth
7.3.1 Need for Continuous Upgrade of RBM Software Products Has Increased the Demand for Services
8 Risk-Based Monitoring Software Market, by Delivery Mode
8.2 Web-Based (On-Demand)
8.2.1 Advantages Such as Easy Access & Reduction in Costs to Support Market Growth
8.3 Licensed Enterprise (On-Premise)
8.3.1 on-Premise Models Minimize Risks Associated With Data Breaches and External Attacks
8.4 Cloud-Based (SaaS)
8.4.1 Increasing Adoption of Cloud-Based Solutions to Drive Market Growth
9 Risk-Based Monitoring Software Market, by End User
9.2 Pharmaceutical & Biopharmaceutical Companies
9.2.1 Increased Pharmaceutical R&D Spending to Drive Market Growth
9.3 Contract Research Organizations (CROs)
9.3.1 Increasing Outsourcing of Clinical Research Activities by Pharmaceutical, Biotechnology, and Medical Device Companies to Drive Market Growth
9.4 Medical Device Companies
9.4.1 Government Funding to Support Market Growth
9.5 Other End Users
10 Risk-Based Monitoring Software Market, by Region
10.2 North America
10.2.1.1 the US Holds the Largest Share of the North American Market
10.2.2.1 Government Funding to Boost Market Growth
10.3.1.1 Initiatives to Boost Digital Health to Propel Market Growth
10.3.2.1 Favorable R&D Scenario in the Country to Boost the Adoption of RBM Software
10.3.3.1 Lack of Sufficient Funding to Restrain Market Growth in France
10.4.1.1 Increased Pharmaceutical R&D Spending to Drive Market Growth
10.4.2.1 Stringent Regulatory Scenario in Japan to Restrain Market Growth
10.4.3.1 Favorable Pharmaceutical R&D Scenario to Drive the Adoption of RBM Software
10.4.4 Rest of Asia-Pacific
10.5 Rest of the World
11 Competitive Landscape
11.2 Market Share Analysis
11.3 Competitive Leadership Mapping
11.3.1 Visionary Leaders
11.3.3 Dynamic Differentiators
11.3.4 Emerging Companies
11.4 Competitive Scenario
11.4.1 Product Launches & Enhancements
12 Company Profiles
12.2 Medidata Solutions
12.3 Parexel (Acquired by Pamplona Capital Management)
12.8 Veeva Systems
12.12 Forte Research Systems
12.13 Mednet Solutions
12.15 Anju Software
12.17 Techsol Corporation
12.19 CRF Health
12.20 Covance Inc.
For more information about this report visit https://www.researchandmarkets.com/r/y6dso3